Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

• Status: NOT_YET_RECRUITING
• Trial end date: 2029-06-27

Summary

The goal of this clinical trial is to investigate the utility of biomarker tools Extracellular Vesicles (EVs), Patient-derived organoid (PDOs), and PDL1 PET imaging for predicting how participants with recurrent NSCLC respond to standard of care treatment in the advanced/metastatic stages.

• Phase: PHASE1

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Carboplatin; Cisplatin; dostarlimab; pembrolizumab; Pemetrexed